(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...

Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...

Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...

Eli Lilly now expects 2024 revenue of $42.4 billion to $43.6 billion, up from its previous forecast of $40.4 billion to $41.6 billion. The drugmaker also raised its annual profit forecast by $1.30 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit Rapidly climbing sales of the ...

Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...

Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...

(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...

(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...

Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...